
Expensive brain-cancer drug no longer an option under Medicare
CBSN
Brain-tumor experts and patient advocates are among those decrying a decision by the seller of a cancer drug to exit a federal discount program for Medicare patients, leaving some unable to afford a treatment that can run as much as $1,000 a capsule.
The move by Miami-based NextSource Biotechnology means the drug Gleostine no longer qualifies for Medicare Part D drug assistance, meaning there is one fewer option of a handful of approved chemotherapies. "There are lots of people right now who are not getting the drug," and some will likely die as a result, Henry S. Friedman, a neuro-oncologist and professor of neurosurgery at Duke University School of Medicine, told CBS MoneyWatch. "There are patients who can't afford the drug, and other drugs may not be as effective."
Elon Musk and the Department of Government Efficiency say they're using their access to the Social Security Administration data not only to investigate claims of waste and fraud, but also to examine claims that immigrants are abusing the system — even though undocumented immigrants contribute more to Social Security than they take.

Washington — A federal judge on Friday rejected an effort by the Justice Department to throw out a Tufts University Ph.D. student's challenge to her detention after she was taken into custody by immigration authorities or have her case moved to Louisiana, finding instead that her case should be transferred to Vermont.

SpaceX Fram2 crew splashes down off California coast to close out historic trip around Earth's poles
A wealthy space tourist and three fellow adventurers plunged back to Earth aboard a SpaceX Crew Dragon capsule Friday, splashing down in the Pacific Ocean off the coast of southern California to close out the first crewed flight around Earth's poles.